Noninvasive assessment of cancer response to therapy (Nat Med, 2008, 14:343-349)

報告日期: 2008/10/31
報告時間: 15:10/16:00
報告學生: 莊智弘
講評老師: 呂佩融

Noninvasive assessment of cancer response to therapy

Han Z, Fu A, Wang H, Diaz R, Geng L, Onishko H, Hallahan DE.

 Nat Med. 2008 Mar;14:343-349


Speaker: Chuang Chih-Hing (莊智弘)

Commentator: Wu, Chao-Liang (呂佩融老師)

Date: 2008/10/31 15:10-16:00

Place Room: 602




Monitoring cancer response to treatment promises to improve our ability to tailor therapy specifically to an individual and rapidly evaluate new pharmaceuticals. So, it is very important to develop a functional imaging system to rapid assessment of cancer response to a therapeutic regimen can determine efficacy early in the course of treatment. To this aim, the author used the Phage-display technology to selected the HVGGSSV peptide for further characterization as an indicator of responsiveness to molecular targeted therapy. However, the author simultaneously assess response in all sites of disease within days of starting therapy by use of peptide ligands selected for their ability to discern responding from nonresponding cancers. When conjugated to near-infrared imaging agents, the HVGGSSV peptide differentiates between these two types of cancer. Rapid, noninvasive assessment of the pharmacodynamic response within cancer promises to accelerate drug development an minimize the duration of treatment with ineffective regimens in cancer patients.



1.   Schueneman, A.J. et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 63, 4009–4016 (2003).

2.   Han, Z., Xiong, C., Mori, T. & Boyd, M.R. Discovery of a stable dimeric mutant of cyanovirin-N (CV-N) from a T7 phage–displayed CV-N mutant library. Biochem. Biophys. Res. Commun. 292, 1036–1043 (2002).